Loading...

RLMD RELMADA THERAPEUTICS INC US FDA Inspections 8-K Filing

RLMD

RLMD

RELMADA THERAPEUTICS INC

(RLMD)

2025 8-K

Corporate Update

Funding Announcement

Management Changes

Corporate Update

Stock Offering Announcement

FDA Feedback Summary

Corporate Update

Compliance Update

Shareholder Update

Stock Purchase Alert

Financial Statements

Transfer of Listing

Divestment of Assets

Product Expansion

Financial Results

License Agreement

Asset Purchase Agreement

Nasdaq Compliance Notice

Management Changes

Study Discontinuation

Annual Meeting of Stockholders

Financial Results

Departure of Directors or C...

Departure of Directors

Earnings Reports

Annual Meeting Approval

Earnings Reports

Earnings Reports

Regulation FD Disclosure

Appointment of Director

Appointment, Presentation U...

Advisory Agreement with Pau...

External Links:

On November 4, 2025, Relmada Therapeutics announced positive FDA feedback for their NDV-01 Phase III trial proposals and shared nine-month safety data showing an 85% complete response rate among patients in their study. The preliminary financial data as of September 30, 2025, indicates $13.9 million in cash and equivalents.

AI Assistant

RELMADA THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.